NCT06192108已完成3 期
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 962
- 试验地点
- 74
- 主要终点
- Change from Baseline in Hemoglobin A1c: (HbA1c)
研究概览
简要总结
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a clinical diagnosis of T2D based on the World Health Organization classification or other locally applicable diagnostic standards.
- •Have HbA1c ≥7.0% (53 mmol/mol) to ≤10.5% (91 mmol/mol) at screening.
- •Have been on stable diabetes treatment with metformin ≥1500 milligram per day (mg/day) during the 90 days prior to screening and maintained through randomization.
- •Are of stable body weight (±5%) for at least 90 days prior to screening and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment.
- •Have a body mass index (BMI) ≥23.0 kilogram/square meter (kg/m²) at screening.
排除标准
- •Have Type 1 Diabetes (T1D)
- •Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
- •Have an estimated glomerular filtration rate (eGFR) <45 milliliter per minute (mL/min)/1.73 square meter (m2)
- •Have acute or chronic hepatitis
- •Have had chronic or acute pancreatitis any time.
- •Have been treated with any antihyperglycemic medication (other than metformin) within the 90 days prior to screening.
研究组 & 干预措施
Orforglipron Dose 3
Experimental
Participants will receive orforglipron orally.
干预措施: Orforglipron (Drug)
Orforglipron Dose 1
Experimental
Participants will receive orforglipron orally.
干预措施: Orforglipron (Drug)
Orforglipron Dose 2
Experimental
Participants will receive orforglipron orally.
干预措施: Orforglipron (Drug)
Dapagliflozin
Active Comparator
Participants will receive dapagliflozin orally.
干预措施: Dapagliflozin (Drug)
结局指标
主要结局
Change from Baseline in Hemoglobin A1c: (HbA1c)
时间窗: Baseline, Week 40
次要结局
- Percentage Change from Baseline in Triglycerides(Baseline, Week 40)
- Percentage of Participants Who Achieved Weight Loss of ≥10% from baseline(Baseline to Week 40)
- Change from Baseline in HbA1c(Baseline, Week 40)
- Change from Baseline in Systolic Blood Pressure (SBP)(Baseline, Week 40)
- Percentage of Participants Who Achieved Weight Loss of ≥5% from Baseline(Baseline to Week 40)
- Percentage Change from Baseline in Total Cholesterol(Baseline, Week 40)
- Percentage of Participants Who Achieved HbA1c <7.0% (53 millimole/mole(mmol/mol))(Week 40)
- Percentage of Participants Who Achieved HbA1c ≤6.5% (48 mmol/mol)(Week 40)
- Percentage Change from Baseline in Body Weight(Baseline, Week 40)
- Change from Baseline in Body Weight(Baseline, Week 40)
- Percentage Change from Baseline in Non-High-Density Lipoprotein (non-HDL)-Cholesterol(Baseline, Week 40)
- Change from Baseline in Diastolic Blood Pressure (DBP)(Baseline, Week 40)
- Change from Baseline in Diabetes Treatment Satisfaction Questionnaire-Change (DTSQc) Scores(Baseline, Week 40)
- Change from Baseline in Fasting Serum Glucose(Baseline, Week 40)
- Percentage of Participants Who Achieved Weight Loss of ≥15% from baseline(Baseline to Week 40)
- Change from Baseline in Short Form 36 Version 2 (SF-36-v2) Acute Form Domain Summary Scores(Baseline, Week 40)
研究者
研究点 (74)
Loading locations...
相似试验
已完成
3 期
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminType 2 DiabetesNCT06045221Eli Lilly and Company1,698
已完成
3 期
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneType 2 DiabetesNCT05971940Eli Lilly and Company559
已完成
3 期
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorType 2 DiabetesNCT06109311Eli Lilly and Company546
已完成
3 期
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskOverweight or ObesityOverweightCardiovascular DiseasesType 2 DiabetesChronic Kidney DiseaseObesityNCT05803421Eli Lilly and Company2,749
已完成
3 期
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseaseObesityNCT05931380Eli Lilly and Company238